27 min

July 14 2023 This Week in Cardiology This Week in Cardiology

    • Science

Carotid stents, the paclitaxel story now closed, inclisiran, DOAC failures, and primary vs secondary prevention are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Carotid Stenting CMS Proposal
Expanded Coverage of Carotid Stenting in CMS Draft Proposal
https://www.medscape.com/viewarticle/994315
No Added Benefit From Revascularization in Low-Risk CAS
https://www.medscape.com/viewarticle/992524
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with Stenting https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&NCAId=311
- Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy
https://doi.org/10.1016/S0140-6736(21)01910-3
- SPACE-2 https://journals.sagepub.com/doi/10.1177/1747493019833017
- Rationale, Design, and Implementation of Intensive Risk Factor Treatment in the CREST2 Trial 10.1161/STROKEAHA.120.030730
II. Paclitaxel
FDA: No Excess Mortality Risk From Paclitaxel Stents, Balloons for Peripheral Intervention https://www.medscape.com/viewarticle/994253
- FDA Statement https://www.fda.gov/medical-devices/letters-health-care-providers/update-paclitaxel-coated-devices-treat-peripheral-arterial-disease-unlikely-increase-risk-mortality?utm_medium=email&utm_source=govdelivery#_FDA_Actions
III. Inclisiran
FDA Expands Inclisiran Statin-Adjunct Indication to Include Primary Prevention https://www.medscape.com/viewarticle/994185
- ORION 10-11 Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol https://www.nejm.org/doi/10.1056/NEJMoa1912387
- Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
https://doi.org/10.1093/eurheartj/ehac615
- Inclisiran and cardiovascular events: a patient-level analysis of phase III trials https://pubmed.ncbi.nlm.nih.gov/36331326/
IV. DOAC Failure
Association of Alternative Anticoagulation Strategies and Outcomes in Patients With Ischemic Stroke While Taking a Direct Oral Anticoagulant
https://doi.org/10.1212/WNL.0000000000207422
V. Primary or Secondary Prevention
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net

Carotid stents, the paclitaxel story now closed, inclisiran, DOAC failures, and primary vs secondary prevention are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Carotid Stenting CMS Proposal
Expanded Coverage of Carotid Stenting in CMS Draft Proposal
https://www.medscape.com/viewarticle/994315
No Added Benefit From Revascularization in Low-Risk CAS
https://www.medscape.com/viewarticle/992524
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with Stenting https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&NCAId=311
- Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy
https://doi.org/10.1016/S0140-6736(21)01910-3
- SPACE-2 https://journals.sagepub.com/doi/10.1177/1747493019833017
- Rationale, Design, and Implementation of Intensive Risk Factor Treatment in the CREST2 Trial 10.1161/STROKEAHA.120.030730
II. Paclitaxel
FDA: No Excess Mortality Risk From Paclitaxel Stents, Balloons for Peripheral Intervention https://www.medscape.com/viewarticle/994253
- FDA Statement https://www.fda.gov/medical-devices/letters-health-care-providers/update-paclitaxel-coated-devices-treat-peripheral-arterial-disease-unlikely-increase-risk-mortality?utm_medium=email&utm_source=govdelivery#_FDA_Actions
III. Inclisiran
FDA Expands Inclisiran Statin-Adjunct Indication to Include Primary Prevention https://www.medscape.com/viewarticle/994185
- ORION 10-11 Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol https://www.nejm.org/doi/10.1056/NEJMoa1912387
- Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
https://doi.org/10.1093/eurheartj/ehac615
- Inclisiran and cardiovascular events: a patient-level analysis of phase III trials https://pubmed.ncbi.nlm.nih.gov/36331326/
IV. DOAC Failure
Association of Alternative Anticoagulation Strategies and Outcomes in Patients With Ischemic Stroke While Taking a Direct Oral Anticoagulant
https://doi.org/10.1212/WNL.0000000000207422
V. Primary or Secondary Prevention
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net

27 min

Top Podcasts In Science

Radiolab
WNYC Studios
Hidden Brain
Hidden Brain, Shankar Vedantam
Something You Should Know
Mike Carruthers | OmniCast Media | Cumulus Podcast Network
Ologies with Alie Ward
Alie Ward
StarTalk Radio
Neil deGrasse Tyson
Sasquatch Chronicles
Sasquatch Chronicles - Bigfoot Encounters

More by Medscape

This Week in Cardiology
Medscape
Medicine and the Machine
Medscape
Keeping Current CME
Medscape
Keeping Current
Medscape Podcasts
One-on-One with Eric Topol
Medscape
The Bob Harrington Show
Medscape